Product Description
Aliskiren is used alone or together with other medicines to treat high blood pressure (hypertension). High blood pressure adds to the workload of the heart and arteries. (Sourced from: https://www.mayoclinic.org/drugs-supplements/aliskiren-oral-route/description/drg-20070895)
Mechanisms of Action: Renin Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Bangladesh | Belgium | Brazil | Canada | Chile | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Egypt | Estonia | European Medicines Agency | Finland | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Italy | Japan | Latvia | Lithuania | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Kingdom | United States | Venezuela | Vietnam
Approved Indications: Myocardial Infarction | Hypertension | Stroke | Hypertension | Acute Myeloid Leukemia | Hypertension
Known Adverse Events: Diarrhea | Edema | Nasopharyngitis | Pharyngitis
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Alzheimer Disease
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2006-7041-83/hah | P1 |
Not yet recruiting |
Alzheimer Disease |
2019-08-30 |